The Medicines Evaluation Board (MEB) assesses and monitors the efficacy, risks and quality of human and veterinary medicinal products, and the safety of novel foods for human consumption.
- Strategic objectives
- Medicines Evaluation Board
- Organisation and units
- Regular consultations
- Independence and integrity
The Board consists of a chairperson and at least 9 and at most 17 other members (doctors, pharmacists and scientists). The chairperson and members are appointed by the Minister of Health, Welfare and Sport (VWS). The term of office of the chairperson and the members is 4 years and can be extended twice for 4 years through reappointment. The Board's method of working and responsibilities are laid down in the Medicines Act.
The members of the Board are supported in their work by more than 300 employees of the Medicines Evaluation Board Agency (MEB Agency). As part of the Ministry of Health, Welfare and Sport (VWS) the Agency is responsible for preparing and implementing decisions by the Board and for coordinating pharmacovigilance in the Netherlands.
The Agency also assesses veterinary medicinal products via the Veterinary Medicinal Products Unit and the assessment of novel foods via the Novel Foods Unit. However, the MEB is not responsible for the decision-making and authorisation of veterinary medicinal products and novel foods. The Veterinary Medicinal Products Unit prepares the decision-making of the Veterinary Medicines Board. This Board advises the Minister of Economic Affairs, who is responsible for policy and politics.
In the Netherlands the Ministry of Health, Welfare and Sport (VWS) is the competent authority for assessment of novel foods. The minister asks the Novel Foods Unit of the MEB for a scientific assessment of consumer safety.
One step closer to less animal testing
In the future, a part of animal testing for new medicines will no longer be necessary. In most cases, testing on one species of...
Science Day 2017 - Generic drugs in society: the regulator’s dilemma
Trust, costs, safety and proper information are the words that regularly recurred during the 6th Science Day of the Medicines...
The Netherlands a candidate for future EMA location
The Netherlands has submitted its candidacy as the country of choice for housing the European Medicines Agency (EMA). The EMA...
Santeon and MEB exchange information about prescription of medicinal products
In the coming year, the Medicines Evaluation Board (MEB) and hospitals affiliated with Santeon will exchange anonymous...
MEB joins European partnership on research into Alzheimer's disease
The Medicines Evaluation Board (MEB), in cooperation with another 22 organisations in 6 countries, is participating in a...